Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac's RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection -- RNActive Vaccine Technology Allows Fast Production in Response to a Pandemic Scenario -- RNActive Vaccines Are Stable at High Temperatures Which Makes Them Suitable for Easy Worldwide Supply -- RNActive Vaccines May Become a Novel, Broadly Applicable and Easy-to-Handle Prophylactic Class of Vaccine Against Infectious Diseases TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research...